SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Co-Development and Option Agreement • January 7th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJanuary 7th, 2019 Company Industry JurisdictionThis Co-Development and Option Agreement (this “Agreement”) is made and entered into effective as of October 16, 2017 (the “Execution Date”) by and between Alector, Inc. (f/k/a Alector LLC), a Delaware corporation (“Licensor”), and AbbVie Biotechnology, Ltd., a Bermuda limited company (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND OPTION AGREEMENTCo-Development and Option Agreement • May 4th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 4th, 2023 Company IndustryThis Amendment No. 1 (this “Amendment”) is effective as of February 13, 2023 (the “Amendment Effective Date”) by and between Alector, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd. (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractCo-Development and Option Agreement • May 8th, 2015 • Biotime Inc • Biological products, (no disgnostic substances)
Contract Type FiledMay 8th, 2015 Company IndustryCertain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission. Confidential portions are marked [**].
CO-DEVELOPMENT AND OPTION AGREEMENTCo-Development and Option Agreement • August 11th, 2014 • Biotime Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 11th, 2014 Company Industry JurisdictionThis Co-development and Option Agreement (“Agreement”) is made by and between the Icahn School of Medicine at Mount Sinai, a nonprofit education corporation organized and existing under the laws of the State of New York, having an office at One Gustave L. Levy Place, New York, New York 10029 (“Mount Sinai”), and LifeMap Solutions, Inc., a corporation organized and existing under the laws of Delaware (“LifeMap”), having a place of business at 1301 Bay Harbor Parkway, Suite 100, Alameda, CA 94502. Mount Sinai and LifeMap are each referred to herein as a “Party” and collectively, as the “Parties.”